Articles for author: Ron Finklestien

March 27, 2024

Ron Finklestien

CareTrust REIT Inc Surpasses Analyst Target: A Signal for Investors

Analyst Reaction to Exceeding Targets Amid recent trading sessions, CareTrust REIT Inc (CTRE) has broken through the average 12-month target price set by analysts, trading at $24.30/share, slightly surpassing the target of $24.25. When a stock achieves the target, analysts typically face a juncture. They may downgrade on valuation grounds or recalibrate the target to a higher mark. This decision may hinge on the core business developments driving the stock’s upward trajectory. If the company is on an upward trajectory, it may prompt an upward revision of the target price. Analyzing the Analysts’ Spectrum Within the realm of Zacks coverage,

March 27, 2024

Ron Finklestien

PVH Corp: Surfing the Wave of Fiscal Success Ahead of Q4 Results PVH Corp: Surfing the Wave of Fiscal Success Ahead of Q4 Results

Anticipated Triumphs in Q4 Earnings Investors eagerly await the unveiling of PVH Corporation’s fourth-quarter fiscal 2023 results on April 1, with expectations riding high on a year-over-year bottom-line upswing. Projections hint at quarterly revenues settling around $2.4 billion, suggesting a marginal 3.2% dip from the comparable figure of the previous year. Positive Outlook and Upward Trajectory Forecasts point to PVH Corporation’s fiscal Q4 earnings standing at $3.50 per share, indicating an inspiring 47.1% growth from the corresponding quarter in the previous year, with a slight uptick in the consensus mark over the past month. Core Brands and Strategic Initiatives Fuel

March 27, 2024

Ron Finklestien

Insightful Analysis on Brighthouse Financial Inc

Roaming the financial jungle, shares of Brighthouse Financial Inc (Symbol: BHF) have sprinted past the average analyst’s 12-month target price of $49.43, trading hands for $49.49/share. When the target is breached, analysts face a pivotal choice: do they pull the valuation rug, or lift the target price to loftier realms? The needle often sways based on the fundamental business tides propelling the stock upward – a wind of change perhaps beckoning a target price raise. Within the vast Zacks coverage landscape, 7 analysts cast their predictions into the BHF horizon, blending their visions to formulate this $49.43 average target. However,

March 27, 2024

Ron Finklestien

The Renaissance of Small-Cap Growth Stocks: Two Hidden Gems to Watch

Setting the Scene: Small-Cap Growth Stocks in a Shifting Landscape In the realm of investing, small-cap growth stocks have long been perceived as the Wild West – full of promise and opportunity, but fraught with risks and challenges. Over the past three years, these stocks have languished in the shadow of their larger counterparts, as the terrain favored giants in artificial intelligence and weight loss drugs. Yet, with the Federal Reserve poised to lower rates, the table may soon turn for these underdogs, potentially heralding a new era of prosperity. Image source: Getty Images. Prime Medicine (NASDAQ: PRME) and Tilray

March 27, 2024

Ron Finklestien

A Closer Look at Two Stocks Poised to Double in 2024

Amidst a sea of volatile stocks, only a handful manage to double their value in a single year. Yet, the real challenge lies in identifying those with the potential for a repeat performance. While market sentiment ebbs and flows like the tide, some stocks carve their path steadily, defying the odds. In this ocean of uncertainties, let’s set our sights on two distinct contenders – SoundHound AI (NASDAQ: SOUN) and Sweetgreen (NYSE: SG) – poised on the precipice of exponential growth this year. Unveiling SoundHound AI’s Resonant Rise For SoundHound AI, the journey towards a lucrative future echoes its previous

March 27, 2024

Ron Finklestien

mining

Mineral Association of Canada Teams Up with Copper Mark to Boost Transparency and Integrity

Innovative Collaboration to Enhance Standards The Mineral Association of Canada (MAC) and Copper Mark have recently joined forces in a groundbreaking partnership designed to augment transparency and credibility in the mining industry. Pierre Gratton, president and CEO of MAC, expressed enthusiasm about the collaboration, emphasizing the valuable exchange that has taken place between the two entities in the past few years. They have worked hand in hand to refine protocols, processes, and policies, propelling this partnership to new heights. Stricter Requirements for TSM Members As a result of this collaboration, members of the Towards Sustainable Mining (TSM) program will experience

March 27, 2024

Ron Finklestien

The Path Forward for Selective Insurance (SIGI) The Path Forward for Selective Insurance (SIGI)

Selective Insurance Group, Inc. SIGI has garnered investor favor due to robust renewal, soaring fuel prices, advantageous excess and surplus (E&S) lines marketplace conditions, and enhanced income from the fixed-income securities portfolio. Upward Growth Trends The Zacks Consensus Estimate for Selective Insurance’s 2024 earnings per share forecasts a 30.3% year-over-year surge while revenue estimates for 2024 stand at $4.86 billion, reflecting a 14.7% increase year-over-year. Looking ahead, the 2025 earnings per share estimate hints at a 10.1% rise year-over-year, with revenue estimates for 2025 projecting $5.31 billion, marking a 9.3% increase over the previous year. An impressive long-term earnings growth

March 27, 2024

Ron Finklestien

The Electric Shock of LINK Stock: Interlink Electronics’ Thunderous Performance in Q4 2023

Source: Stanslavs / Shutterstock.com Interlink Electronics (NASDAQ:LINK) has electrified investors with the unveiling of its results for the final quarter of 2023. The thunderous performance saw Interlink Electronics reporting earnings per share of -6 cents. The colossal company generated a striking revenue of $3.54 million. InvestorPlace Earnings has unleashed a financial tempest, utilizing data from TradeSmith to present an automated exposé on quarterly profits. The lightning-fast reports distill critical insights involving earnings per share, revenue, and the correlation with expert forecasts. These articulations are orchestrated sans human intervention, ensuring that the latest numeric saga reaches the audience posthaste. Concerns or

March 27, 2024

Ron Finklestien

The Rise of Cencora (COR): A Prescient Investment Move

Reasons to Consider the Surge in Cencora (COR) Stock Cencora, Inc. COR stands at the threshold of a lucrative growth phase, propelled by its robust U.S. Healthcare Solutions division and a flurry of new product unveilings. Despite the looming shadow of fierce competition, the stock has soared by 18.2% year-to-date, eclipsing the industry’s 5.8% ascend. In comparison, the S&P 500 Index has inched up by 9.3% over the same time period. A Gargantuan in the Pharmaceutical Realm Cencora proudly stands as one of the globe’s largest pharmaceutical service behemoths, specializing in drug distribution and ancillary services aimed at curbing healthcare

March 27, 2024

Ron Finklestien

McCormick & Co Inc Surpasses Average Analyst Target: Time to Sprinkle Some Insight into Your Portfolio?

As trading heats up, McCormick & Co Inc (Symbol: MKC) shares have soared above the average analyst 12-month target of $70.91, clocking in at $77.30/share. When a stock zooms past the target mark, analysts face a fork in the road: downgrade for valuation or notch the target up. This reaction hinges on the fundamental business dynamics propelling the stock up — if the company is set for a sunny spell, it might just be target-raising time. Within the Zacks coverage universe, 11 distinct analyst targets shape McCormick & Co Inc’s average. Yet, the mean is just that – a statistical